OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII

被引:0
|
作者
Toschi, Vincenzo [1 ]
机构
[1] San Carlo Borromeo Hosp, Dept Hematol & Blood Transfus, I-20153 Milan, Italy
关键词
INHIBITORS; PROPHYLAXIS; REDUCTION; HISTORY; FUTURE; SAFETY; MICE; CARE;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Hemophilia A is caused by a deficiency in blood coagulation Factor (F) VIII. Treatment for acute bleeding in patients comprises prophylactic infusion with human plasma-derived (pd) or recombinant (r)FVIII to increase circulating FVIII levels. However, alloantibodies (inhibitor) may arise in patients, limiting the efficacy of replacement therapy, especially in patients who develop high-titer inhibitors. For these patients, FVIII-bypassing agents are proposed, but there is a rare risk of thrombotic events. Porcine pdFVIII successfully achieves hemostatic FVIII levels in patients in whom human FVIII was ineffective, but possible residual viral contamination and immunogenicity prevents routine use. OBI-1, being developed by Ipsen and Inspiration Biopharmaceuticals Inc, is a bioengineered form of porcine rFVIII that is highly purified. OBI-1 has the procoagulant and biochemical properties of porcine pdFVIII, with improvements in risk of toxicity, infection and ease of manufacture. OBI-1 demonstrated significantly less immunogenicity than pdFVIII in a murine model of hemophilia A. Moreover, in cynomolgus monkeys, OBI-1 did not generate detectable inhibitors. OBI-1 was effective in a phase II, open-label clinical trial in patients with hemophilia A and inhibitor against porcine FVIII, who were experiencing a non-life or -limb threatening bleed. OBI-1 was well tolerated, without drug-related serious adverse events and is promising for further studies.
引用
收藏
页码:617 / 625
页数:9
相关论文
共 50 条
  • [1] Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A
    Riaz, Muhammad Kashif
    Girnius, Saulius
    Palascak, Joseph Edward
    [J]. BLOOD, 2015, 126 (23)
  • [2] Overview of the structure and manufacturing process for OBI-1, a recombinant porcine sequence, factor VIII for the treatment of acquired hemophilia A
    Wojciechowski, Peter
    Lai, Chee Kong
    Xiong, Yi
    Deer, Frank
    [J]. HAEMOPHILIA, 2014, 20 : 181 - 181
  • [3] The Benefit of FVIII Measurement: Tailored Treatment with Obi-1, a Recombinant Porcine Sequence Factor VIII, in Subjects with Acquired Hemophilia a
    Oladapo, Abiola
    Epstein, Joshua
    Novack, Aaron
    Farin, Heinrich D.
    [J]. BLOOD, 2014, 124 (21)
  • [4] Treatment of serious bleeds with an antihaemophilic factor VIII (recombinant), porcine sequence (OBI-1) in patients with acquired haemophilia A
    Kruse-Jarres, R.
    St-Louis, J.
    Greist, A.
    Shapiro, A.
    Smith, H.
    Chowdary, P.
    Drebes, A.
    Gomperts, E.
    Bourgeois, C.
    Mo, M.
    Novack, A.
    Farin, H.
    Ewenstein, B.
    [J]. HAEMOPHILIA, 2015, 21 : 62 - 62
  • [5] The Effect of Inhibitory Antibodies on Acute Treatment of Bleeding Episodes with OBI-1, an Antihemophilic Factor VIII (recombinant), Porcine Sequence, in Patients with Acquired Hemophilia A
    Farin, Heinrich D.
    Novack, Aaron
    Mo, Min
    Bourgeois, Christelle
    Horling, Frank M.
    Ewenstein, Bruce M.
    [J]. BLOOD, 2014, 124 (21)
  • [6] Efficacy and safety of B-domain deleted recombinant porcine factor VIII (OBI-1) in the treatment of acquired hemophilia A: interim results
    Greist, A.
    Shapiro, A.
    Kruse-Jarres, R.
    St Louis, J.
    Smith, H.
    Gomperts, E.
    [J]. HAEMOPHILIA, 2012, 18 : 1 - 1
  • [7] Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results
    St Louis, Jean
    Kruse-Jarres, Rebecca
    Greist, Anne
    Shapiro, Amy D.
    Smith, Hedy
    Drebes, Anja B.
    Lozier, Jay N.
    Gomperts, Edward D.
    [J]. BLOOD, 2012, 120 (21)
  • [8] Recombinant porcine sequence factor VIII (OBI-1): Results from a prospective clinical study investigating the treatment of serious bleeds in patients with acquired hemophilia A
    Kruse-Jarres, R.
    St-Louis, J.
    Greist, A.
    Shapiro, A.
    Smith, H.
    Chowdary, P.
    Drebes, A.
    Gomperts, E.
    Chapman, M.
    Mo, M.
    Novack, A.
    Farin, H.
    [J]. HAEMOPHILIA, 2014, 20 : 1 - 1
  • [9] TREATMENT OF SERIOUS BLEEDS IN A PROSPECTIVE CLINICAL TRIAL WITH A B-DOMAIN DELETED RECOMBINANT PORCINE SEQUENCE FACTOR VIII (OBI-1) IN PATIENTS WITH ACQUIRED HEMOPHILIA A
    Kruse-Jarres, Rebecca
    St-Louis, Jean
    Greist, Anne
    Shapiro, Amy
    Smith, Hedy
    Chowdary, Pratima
    Drebes, Anja
    Gomperts, Edward
    Chapman, Miranda
    Mo, Min
    Novack, Aaron
    Farin, Heinrich
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E41 - E42
  • [10] Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
    Kruse-Jarres, R.
    St-Louis, J.
    Greist, A.
    Shapiro, A.
    Smith, H.
    Chowdary, P.
    Drebes, A.
    Gomperts, E.
    Bourgeois, C.
    Mo, M.
    Novack, A.
    Farin, H.
    Ewenstein, B.
    [J]. HAEMOPHILIA, 2015, 21 (02) : 162 - 170